ISPP 2015

Career Opportunities in Pharmacy
Biotechnology: Anti Aging, Cloning, Stem Cells, and Beyond – interview with Dr. Demetri

this is dr. Nick Delgado we’re at rad
fest and we’re with Demetri yeah yes let me throw ya it’s about the same you just
did a talk give me a summary of that talk I want to know the key points of
what our audience needs to know about true anti-aging and potentially that
people here want to learn how maybe they can go beyond what no person has ever
reached in biological agent yeah well if to summarize the entire lecture the
entire presentation please we have every Asian person every person who is
developing or has already developed a chronic age-related degenerative disease
is facing two problems the first one is that you have to regenerate tissue right
whatever tissue is affected but it is practically impossible to do that if you
do not address to the main mechanisms that have actually caused that tissue
degeneration yeah and those mechanisms people define it outside the seven eight
pillars of aging or like Aubrey de Grey said the seven deadly things those are
the pathological well not really pathological because in an early stage
it’s it has that some biological benefit in terms of the wound healing and then
tissue remodeling and all but as long as the the products of the tissue
metabolism that collective secret all is reaching some particular point some
critical limit critical level it’s not causing the detrimental effects of the
tissues it caused the chronic inflammation and cause the tissue
degeneration so whatever you want to do for the patient you have to keep those
two things in mind so the number one steps should address
the seven ages 7 pillars of aging yeah yes and that means all the day
Ambika activators the respirator old and and mTOR inhibitors you know the whole
is so that means the nad and all it’s absolutely a yes without that you cannot
slow down or reverse aging on the cellular level
my while doing that you need to do the tissue repair and the tissue repair can
be done only by the means of the cell therapy here so it’s with the stem cells
so we’re talking about different types of the stem cells the stem cells which
are less differentiated they’re more multi potent or the bureau reporter yeah
or the MSC is you know and they have a wonderful beneficial effect in terms of
reducing the level of systemic inflammation but they are not capable of
tissue regeneration the MSE is which you infuse in the body they practically
never differentiate in convert and never convert into cells which comprise our
body yeah so they just cause the general paracrine effect yeah but they don’t do
the tissue repair so the tissue repair is possible with a unipotent or highly
specialized precursor or also known as progenitor cells so those cells are they
sell specifics so for example if you’re trying to heal the brain you collect
those specific cells that are directly from the brain of an organism well let’s
not use the word collect okay we’re at culture okay it’s a biotechnological
process well yes they do they are derived or procured from fetal tissue
and and usually we use the laboratory lab animals for that same as the pharma
companies they use those same animals for manufacturing of about 10,000
different drugs medications which are from the animal origin yeah so but the
cells are not directly administered to the patient they go through the biotech
process and in the process called culturing so they go through the various
few passages of the cells yeah and at every step there’s a confirmation that
these cells do not do something wrong you know so there’s no genetic
abnormalities detected there you know whatsoever you know and then of course
the various three microbiological control as well particularly because
they’re de0 barely not even a day old the
possibility of them replicating with perfect duplicates is very good when we
reach 40 50 60 those cells have had a lot of potential mutations true
oh yes and then there’s a absolute there’s a common knowledge now in a
medical and scientific community that as we age our stem cells age as well
yeah and I’m also happy to find out that there’s more and more practitioners and
even here in the United States who would not do autologous cell therapy for
patients who are older than 40 years old yeah right because if you’re giving
someone who’s 45 50 60 these cells have so much problems with them they’re not
going to elicit or even help people to get the kind of benefit that we’re
hoping for is that true there are chances that things may get worse you
know you know this MSE one and let me say to you know to type of cell some
anti-inflammatory some may even have the bra inflammatory characteristics you
know so it means that when you expect that you’re gonna reduce the systemic
inflammation you actually make it worse nobody wants that to happen now I know
you’re a co-author of a book on stem cells you’re a co-author on a book on
biological medicine I believe there’s another book in the pipeline on cellular
we’re working on why which is more just a general audience oriented and at the
same time I think it’s right time to do the second edition and we’re looking for
some way we have some scientific collaborators here in the United States
who would like to work with us on the second edition of the book I’ve read
your books are well referenced they’re easy to understand from a scientific
perspective and also even the lay public for those who want to delve deep into
understanding the correct way to go about helping the body to rejuvenate
what we’re talking about is regenerative medicine right so at this stage this is
something that’s been around though and you have looked at the pioneering
clinics in Germany Switzerland Japan is looking at this work as well right s
plenty of countries in the world that have been doing that and are doing it
now and although it is not really welcomed much by some of the FDA’s of
some of the countries and some of the education educational institutions are
also not really paying much attention to the stem cells but I think it’s you
can’t deny the fact that it’s biologically substance
you can’t deny the fact that this probably cell therapies probably one of
the few or maybe the only way of effective tissue regeneration and sooner
or later it will be available to general public and in general hospitals but
probably not you’re in our lifetime yeah sadly Dmitry I know you work with
European Wellness tell me a little bit about your background as a doctor and
your training I mean how did you get to a place where you could write these
textbooks and speak in front of an audience I was just lucky okay
I was lucky yeah well I was born in a medical family my father’s a surgeon my
grandma is a pharmacologist you know so it sort of I had no other options you
know in life and apart from being a surgeon my father is also a plastic
surgeon and when I during my university years in 1990s month that time my father
was already working with the stem cells and regenerative medicine and also sort
of I was observing all of this I did not have much of interest that time because
I was quite idealistic parents just Center in medicine and you think of
doing major surgeries rather than regenerative preventive medicine and
I’ve done my post-grad in surgery shortly after they have done the PhD in
reconstructive surgery and I was lecturing I was working a clinical setup
then something some changes happen in my personal life
so I migrated I changed not only the country but the whole anti continent and
I believe that I’m blessed you know for that because I had wonderful privilege
and working in different countries and different medical systems and all and
I’ve learned a lot and yeah but there’s some way along the way also I was very
fascinated with the liver surgery and even in 2012-2013 I want the grant from
the Japan Society of liver surgeons and for the study that I’ve done while
working in Malaysia and I was invited to be a speaker in Japan you know so it was
like really wonderful experience and all and some way along that way I had those
thoughts you know it’s like when I’m 55 or 60 years old would I want to do the
same that I’m doing and by was quite honest with myself and
I said no so it means that ten years before that happens I have to change my
career and I I knew about what dr. Mike is doing and I knew the people in this
group and I met them they offered me job and I took it you know and I’ve done a
post doctorate in regenerative medicine tissue engineering after that I’m
absolutely happy with what I do is it correct to say that there are potential
benefits for the following conditions with selecting the right type of cell
tissues for the brain possibly for autism for ALS possibly dementia
Alzheimer’s dementia yes ALS well LS is a tricky question yeah because in order
to effectively treat the disease we have to understand the nature of the disease
completely okay with the LS it well we sort of we do understand it but it’s
such a disseminated pathology you know that difficult to know where to start
you know so it’s not really curable at this moment but at least we can extend
the lifespan of the patients autism angle is mongoloid ism age-related are
the neurodegenerative disease such as the packin Sun dimensional science
and/or concern I would and it’s not only my opinion yeah you can read it it’s
published in a peer reviews and all but the stem cell transplantation and cell
therapy is the golden standard for treatment of those diseases it’s not
commonly accepted yet but biologically and scientifically there’s a very strong
background for that and definitely that’s a golden standard cardiomyopathy
homeopathy absolutely is diabetes it depends diabetes type 1 or diabetes type
2 and then you see there’s a very interesting thing if you look at the
clinical trials targeting DM type one is about 20-25 years ago with the cell
therapy so you see that the efficacy was about 40 50 percent it was like half
half half of the patients did benefit well half of them not
I believe it’s because the understanding of the disease those days in a center of
the disease now is different a few years ago there was a so-called the
Scandinavian trial published and they have proposed the new classification of
diabetes it’s not type 1 type 2 anymore they have five clusters of diabetes Wow
yeah so it’s a very interesting thing so if you look at the outcomes from the
point of view of the five clusters of diabetes you will be able to understand
why cell therapy works for some patients and it doesn’t work for other patients
like in the case of the autoimmune and diabetes or the latent autoimmune
diabetes you know it doesn’t work that well now we know why you know so you
probably better address that with a immunotherapy rather than with the stem
cells you know but when for other forms of the diabetes here retinopathy loss of
sight difficult to do but possible it’s possible and probably it’s not more the
stem cells but more the retinal peptides that would solve the problem now I know
you’ve done a lot of work with peptides and mitochondria organelles is that true
and so just the cell extracts basically it’s from the same realm as the exams
and all these other cell x secretions you know so or the secret home of the
cells or the cell extracts and then they are the different types some of them
anonymize it depends on the molecular weight you know the actual peptide and
aging itself is it possible to intervene with multiple therapies from in a
biological sense that we’re talking about so hopefully we can reverse 10-15
years of age well I would hope that 10 15 years mine
probably someday in future you know we start with a less amount of years 5%
maybe probably yeah we start with that and then see how it goes
beautiful dr. Nick Delgado and Demetri and please check out European Wellness
and please share this with those who are interested in living a longer better
quality life take care be well it’s a great pleasure thank you thank you

Leave comment

Your email address will not be published. Required fields are marked with *.